Search

Your search keyword '"Brinda Emu"' showing total 57 results

Search Constraints

Start Over You searched for: Author "Brinda Emu" Remove constraint Author: "Brinda Emu"
57 results on '"Brinda Emu"'

Search Results

2. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)

Catalog

Books, media, physical & digital resources

3. Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis

4. Impact of illicit opioid use on T cell subsets among HIV-infected adults.

5. Composition and function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease.

6. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers.

7. Human Immunodeficiency Virus Is Associated With Poor Overall Survival Among Patients With Head and Neck Cancer

8. Serum Neutralizing Antibody Titers 12 Months After Coronavirus Disease 2019 Messenger RNA Vaccination: Correlation to Clinical Variables in an Adult, US Population

9. Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting for patients undergoing antineoplastic treatment for cancer

10. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium

11. Building an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center’s Experience and Reflections

12. Cancer Microbiology

13. 437 Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium

14. Alterations in high‐dimensional T‐cell profile and gene signature of immune aging in <scp>HIV</scp> ‐infected older adults without viremia

15. HIV is associated with poor overall survival among head and neck cancer patients

16. Correlation between CD4/CD8 ratio and neurocognitive performance during early HIV infection

17. Clinical Variables Correlate with Serum Neutralizing Antibody Titers after COVID-19 mRNA Vaccination in an Adult, US-based Population

18. Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV

19. Serum Neutralizing Antibody Titers 12 months after COVID-19 mRNA Vaccination: Correlation to Clinical Variables in an Adult, US-Population

20. PD-1highCXCR5–CD4+ peripheral helper T cells promote CXCR3+ plasmablasts in human acute viral infection

21. PD-1

22. Abstract 418: Lower survival among HIV-infected head and neck cancer patients

23. Palliation of malignancies in HIV infection

24. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

25. PD-1highCXCR5–CD4+ Peripheral Helper T (Tph) cells Promote Tissue-Homing Plasmablasts in COVID-19

26. Impact of HIV infection on clinical outcomes among people diagnosed with head and neck cancer

27. Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis

28. Oxidized Lipids and CD36-Mediated Lipid Peroxidation in CD8 T Cells Suppress Anti-Tumor Immune Responses

29. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors

30. Clinically significant mutations in HIV-infected patients with lung adenocarcinoma

31. Exosomal MicroRNAs Associate With Neuropsychological Performance in Individuals With HIV Infection on Antiretroviral Therapy

32. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study

33. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

34. HIV and Age Do Not Synergistically Affect Age-Related T-Cell Markers

35. Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults

36. Photo Quiz: Peripheral Blood Smear in a Ugandan Refugee

37. Case report of the patient source of the Babesia microti R1 reference strain and implications for travelers

38. 661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)

39. P1.04-23 Characterizing the Tumor Immune Microenvironment of Non-Small Cell Lung Carcinoma in People Living with HIV Using Imaging Mass Cytometry

40. Phase I study of pembrolizumab in people with HIV and cancer

41. Epigenome-wide differential DNA methylation between HIV-infected and uninfected individuals

42. Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer

43. Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1

44. Relationship between T Cell Activation and CD4+T Cell Count in HIV‐Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy

45. Loss of T cell responses following long-term cryopreservation

46. Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment

47. Answer to December 2017 Photo Quiz

48. Impact of illicit opioid use on T cell subsets among HIV-infected adults

49. Composition and function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease

50. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers